Drugs & Targets AmerisourceBergen establishes Clinical Trial Navigator tool to increase access to research opportunities May 27, 2022Vol.48 No.21
Drugs & Targets Paige Prostate Biomarker Suite receives CE-IVD and UKCA marks May 20, 2022Vol.48 No.20
Drugs & Targets Cancer Research UK, Oncode Institute form strategic alliance May 13, 2022Vol.48 No.19
Drugs & Targets RaySearch, GE Healthcare collaborate to improve radiation oncology treatment planning May 13, 2022Vol.48 No.19
Drugs & Targets BridgeBio, BMS to develop and commercialize SHP2 inhibitor BBP-398 May 13, 2022Vol.48 No.19
Drugs & Targets Cullinan Oncology, Taiho Pharmaceutical to develop and commercialize CLN-081/TAS6417 for NSCLC May 13, 2022Vol.48 No.19
Drugs & Targets Imfinzi + chemo granted FDA Priority Review for locally advanced or metastatic biliary tract cancer May 06, 2022Vol.48 No.18
Drugs & Targets Aptose granted Fast Track Designation from FDA for HM43239 in relapsed/refractory AML patients and FLT3 Mutation May 06, 2022Vol.48 No.18
Drugs & Targets EC approves Kymriah in relapsed or refractory follicular lymphoma May 06, 2022Vol.48 No.18
